We consider the control of formations of a leader-follower network, where the objective is to steer a team of multiple mobile agents into a formation of variable size. We assume that the shape description of the formation is known to all the agents, which is captured by a complex-valued Laplacian associated with the sensing graph, but the size scaling of the formation is not known or only known to two agents, called the leaders in the network. A distributed linear control strategy is developed in this paper such that the agents converge to the desired formation shape, for which the size of the formation is determined by the two leaders. Moreover, in order to make all agents in a formation move with a common velocity, the distributed control law also incorporates a velocity consensus component, which is implemented with the help of a communication network that may, in general, be of different topology from the sensing graph. Both the setup of single-integrator kinematics and the one of double-integrator dynamics are addressed in the same framework except that the acceleration control in the double-integrator setup has an extra damping term.

Download full-text PDF

Source
http://dx.doi.org/10.1109/TCYB.2015.2477107DOI Listing

Publication Analysis

Top Keywords

size scaling
8
agents formation
8
formation agents
8
sensing graph
8
formation
7
agents
5
formation control
4
size
4
control size
4
scaling complex
4

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Signant Health, Blue Bell, PA, USA.

Background: Clinical trial sponsors rely on research sites to identify and enroll appropriate study participants and to correctly and reliably assess symptom severity and function over the course of the trial. Low-recruiting sites represent a large financial and operational burden and may negatively impact trial success either by selecting inappropriate participants and/or high prevalence of data quality issues. We previously reported that >60% of sites in schizophrenia clinical trials recruited ≤5 participants.

View Article and Find Full Text PDF

Background: Gamma desynchronization is an early pathophysiological event in Alzheimer's disease with a disturbance in oscillation in the gamma frequency range 30-80 Hz. This disruption was found to be directly related to the disease progression and severity. Thus, the use of transcranial alternating current stimulation (tACS) possessed greater interest.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Unlearn.AI, San Francisco, CA, USA.

Background: Pivotal Alzheimer's Disease (AD) trials typically require thousands of participants, resulting in long enrollment timelines and substantial costs. We leverage deep learning predictive models to create prognostic scores (forecasted control outcome) of trial participants and in combination with a linear statistical model to increase statistical power in randomized clinical trials (RCT). This is a straightforward extension of the traditional RCT analysis, allowing for ease of use in any clinical program.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

AbbVie Inc., North Chicago, IL, USA.

Background: In Alzheimer's Disease (AD) trials, clinical scales are used to assess treatment effect in patients. Minimizing statistical uncertainty of trial outcomes is an important consideration to increase statistical power. Machine learning models can leverage baseline data to create AI-generated digital twins - individualized predictions (or prognostic scores) of how each patient's clinical outcomes may change during a trial assuming they received placebo.

View Article and Find Full Text PDF

Background: Behavioral and psychological symptoms of dementia (BPSD) occur frequently in persons with Alzheimer's disease (PAD). They cause suffering, institutionalization, carepartner distress, depression, burden, and decreased PAD-carepartner quality of life. Brexpiprazole approval advanced the AD treatment armamentarium.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!